GlassScriptPhysician profile
Jamie Pare
NPI 1558035709
$3,661.71
in general payments reported to CMS, 2019-2025
32 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $741 · 2023: $1,054 · 2024: $1,008 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.08 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $388.50 | 2021-2024 | Ultomiris, Soliris |
| Pfizer INC. | $303.13 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $285.27 | 2023-2025 | Nuplazid |
| Medtronic, INC. | $231.10 | 2021-2024 | Percept PC Brainsense |
| Takeda Pharmaceuticals U.S.A., INC. | $190.16 | 2022-2024 | Gammagard, Hyqvia |
| Neurocrine Biosciences, INC. | $175.15 | 2024-2025 | Ingrezza |
| Mdd US Operations, LLC | $165.68 | 2023 | Apokyn |
| Janssen Pharmaceuticals, INC | $144.99 | 2021-2024 | Xarelto |
| Lundbeck LLC | $136.89 | 2022-2025 | Vyepti |
| Pacira Pharmaceuticals Incorporated | $122.55 | 2022 | |
| Ucb, INC. | $102.74 | 2023-2025 | Briviact, Rystiggo, Zilbrysq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2021 | |
| Neurelis, INC. | $93.51 | 2022-2025 | Valtoco |
| Lilly USA, LLC | $92.83 | 2023-2025 | Amyvid, Kisunla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $91.53 | 2023-2025 | Hizentra, Kcentra |
| Teva Pharmaceuticals USA, INC. | $90.45 | 2023-2024 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $87.83 | 2022-2025 | Onpattro |
| Merz Pharmaceuticals, LLC | $83.71 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Argenx US, INC. | $73.86 | 2022-2023 | Vyvgart |
| Acorda Therapeutics, INC | $46.13 | 2023-2024 | Inbrija |
| Emd Serono, INC. | $41.05 | 2024 | |
| Biogen, INC. | $35.12 | 2024-2025 | Skyclarys |
| Jazz Pharmaceuticals INC. | $34.13 | 2022 | |
| Averitas Pharma INC. | $28.30 | 2025 | Qutenza |
| Sk Life Science, INC. | $22.37 | 2024 | |
| Amneal Pharmaceuticals LLC | $21.14 | 2023 | Rytary |
| Tanabe Pharma America, INC. | $20.25 | 2024 | |
| Springworks Therapeutics, INC. | $15.06 | 2025 | |
| Impel Pharmaceuticals INC. | $14.29 | 2023 | Trudhesa |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kyowa Kirin, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Pare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.